Currently, antibody drugs have grown to be the dominant products in the biopharmaceutical market for the treatment of many diseases. Especially in tumor drug research, monoclonal anti-tumor drugs have been widely used because of their high specificity, low incidence of adverse reactions, and good patient tolerance!

To fully serve pharmaceutical companies' demand for high quality recombinant antibodies, CUSABIO is offering the following recent popular "Drug-Like" Antibodies, which function as Biopharmaceutical Benchmarks: DLL3 Monoclonal Antibody; GCGR Monoclonal Antibody; SEMA4D Monoclonal Antibody; MERTK Monoclonal Antibody; CCR8 Monoclonal Antibody; CLDN18 Monoclonal Antibody; Claudin-18.2 Monoclonal Antibody

In addition to its own competitive advantages, CUSABIO boasts the optimal system for the production of recombinant antibodies with superior purity, stronger affinity, and greater consistency from batch to batch.

Popular "Drug-Like" Antibodies as Benchmarks:

SEMA4D Monoclonal Antibody (CSB-RA835707A1HU)

CLDN18 Monoclonal Antibody (CSB-RA005498A2HU)

Claudin-18.2 Monoclonal Antibody (CSB-RA005498A1HU)

DLL3 Monoclonal Antibody (CSB-RA882142A1HU)

MERTK Monoclonal Antibody (CSB-RA621519A1HU)		CCR8 Monoclonal Antibody (CSB-RA004847A1HU)